1. Home
  2. CYCN vs KZIA Comparison

CYCN vs KZIA Comparison

Compare CYCN & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYCN
  • KZIA
  • Stock Information
  • Founded
  • CYCN 2018
  • KZIA 1994
  • Country
  • CYCN United States
  • KZIA Australia
  • Employees
  • CYCN N/A
  • KZIA N/A
  • Industry
  • CYCN Biotechnology: Pharmaceutical Preparations
  • KZIA Biotechnology: Pharmaceutical Preparations
  • Sector
  • CYCN Health Care
  • KZIA Health Care
  • Exchange
  • CYCN Nasdaq
  • KZIA Nasdaq
  • Market Cap
  • CYCN 8.4M
  • KZIA 7.8M
  • IPO Year
  • CYCN N/A
  • KZIA 1999
  • Fundamental
  • Price
  • CYCN $4.21
  • KZIA $1.29
  • Analyst Decision
  • CYCN
  • KZIA Strong Buy
  • Analyst Count
  • CYCN 0
  • KZIA 2
  • Target Price
  • CYCN N/A
  • KZIA $11.50
  • AVG Volume (30 Days)
  • CYCN 5.8M
  • KZIA 5.5M
  • Earning Date
  • CYCN 03-04-2025
  • KZIA 03-26-2025
  • Dividend Yield
  • CYCN N/A
  • KZIA N/A
  • EPS Growth
  • CYCN N/A
  • KZIA N/A
  • EPS
  • CYCN N/A
  • KZIA N/A
  • Revenue
  • CYCN $194,000.00
  • KZIA $1,655,324.00
  • Revenue This Year
  • CYCN N/A
  • KZIA $806.89
  • Revenue Next Year
  • CYCN N/A
  • KZIA N/A
  • P/E Ratio
  • CYCN N/A
  • KZIA N/A
  • Revenue Growth
  • CYCN N/A
  • KZIA 248000.00
  • 52 Week Low
  • CYCN $1.27
  • KZIA $1.25
  • 52 Week High
  • CYCN $9.47
  • KZIA $15.80
  • Technical
  • Relative Strength Index (RSI)
  • CYCN 58.42
  • KZIA 39.50
  • Support Level
  • CYCN $2.81
  • KZIA $1.31
  • Resistance Level
  • CYCN $6.25
  • KZIA $2.64
  • Average True Range (ATR)
  • CYCN 0.67
  • KZIA 0.24
  • MACD
  • CYCN 0.17
  • KZIA 0.09
  • Stochastic Oscillator
  • CYCN 48.35
  • KZIA 14.29

About CYCN Cyclerion Therapeutics Inc.

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.

Share on Social Networks: